18. 脊髄小脳変性症(多系統萎縮症を除く。) Spinocerebellar degeneration Clinical trials / Disease details


臨床試験数 : 71 薬物数 : 101 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04921930
(ClinicalTrials.gov)
July 1, 202131/5/2021Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA) Phase I-II Efficacy-Toxicity of Artesunate in Friedreich AtaxiaFriedreich AtaxiaDrug: Artesunate Oral ProductInstitut National de la Santé Et de la Recherche Médicale, FranceImagine InstituteNot yet recruiting16 Years65 YearsMale20Phase 1/Phase 2NULL
2EUCTR2021-000171-36-FR
(EUCTR)
23/03/202122/01/2021PHASE I-II EFFICACY-TOXICITY OF ARTESUNATE IN FRIEDREICH ATAXIA (FA)PHASE I-II EFFICACY-TOXICITY OF ARTESUNATE IN FRIEDREICH ATAXIA Friedreich Ataxia
MedDRA version: 20.0;Level: PT;Classification code 10017374;Term: Friedreich's ataxia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: artesunateINSERMNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
22Phase 1;Phase 2France